Announced Wed, 29 Apr · 16:12 IST

Submission of Audited Standalone Financial Results for the quarter and financial year ended March 31, 2026

Pat NegativeExceptional ItemEbitda Margin CompressionResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-4.6%1-day move
₹45.50
prior close
₹45.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0-2.2-2.0+1.8-4.6-4.6-0.9+4.1+5.4-1.1-3.3-4.4-3.3
Up moveDown movePending
AI summary

Zenotech Laboratories reported a net loss of Rs 107.21 lakhs for FY2026, a sharp decline from profit of Rs 561.29 lakhs in FY2025. Revenue from operations grew marginally by 1.5% to Rs 3,956.20 lakhs. Profit before tax dropped significantly to Rs 418.90 lakhs from Rs 1,069.19 lakhs in the previous year. The company recorded exceptional items of Rs 19.51 lakhs due to Labour Code changes. Tax adjustments were substantial, including MAT credit reversal of Rs 187.47 lakhs and deferred tax charge of Rs 157.82 lakhs. Despite the loss, operating cash flow remained positive at Rs 1,020.48 lakhs. The statutory auditor issued an unmodified (clean) opinion on the financial statements.

Likely market impact

The company turned loss-making in FY2026 with PAT negative, primarily due to increased expenses and significant tax reversals. However, strong cash generation and clean audit opinion provide some comfort to shareholders.